✦ LIBER ✦

High-dose glucocorticoids plus Ofatumumab in fludarabine/alemtuzumab-resistant B-cell chronic lymphocytic leukemia

✍ Scribed by Vannata, Barbara; Innocenti, Idanna; Autore, Francesco; Sorà, Federica; Chiusolo, Patrizia; Leone, Giuseppe; Sica, Simona; Laurenti, Luca

Book ID: 118751078
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 49 KB
Volume: 87
Category: Article
ISSN: 0361-8609
DOI: 10.1002/ajh.23349

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The use of low-dose alemtuzumab in pretr

The use of low-dose alemtuzumab in pretreated B-cell chronic lymphocytic leukemia

✍ Tarnani, M; D'Arena, G; Efremov, D G; Marietti, S; S, Sica; Leone, G; Laurenti, 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 116 KB

High-dose dexamethasone in refractory B-

High-dose dexamethasone in refractory B-cell chronic lymphocytic leukemia patients

✍ Stefano Molica 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 1 views

Complement dependent cytotoxicity in chr

Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement

✍ Baig, Nisar A.; Taylor, Ronald P.; Lindorfer, Margaret A.; Church, Amy K.; Lapla 📂 Article 📅 2012 🏛 Informa plc 🌐 English ⚖ 436 KB

An open-label, pilot study of fludarabin

An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia

✍ Montillo, M.; Tedeschi, A.; Petrizzi, V. B.; Ricci, F.; Crugnola, M.; Spriano, M 📂 Article 📅 2011 🏛 American Society of Hematology 🌐 English ⚖ 147 KB

High-risk fludarabine-pretreated B-cell

High-risk fludarabine-pretreated B-cell chronic lymphocytic leukemia's high response rate following sequential DHAP and alemtuzumab administration though in absence of molecular remission

✍ Ignazio Majolino; Marco Ladetto; Anna Locasciulli; Daniela Drandi; Fabio Benedet 📂 Article 📅 2006 🏛 Springer US 🌐 English ⚖ 117 KB

Efficacy and safety of low-dose alemtuzu

Efficacy and safety of low-dose alemtuzumab as treatment of autoimmune hemolytic anemia in pretreated B-cell chronic lymphocytic leukemia

✍ Laurenti, L; Tarnani, M; Efremov, D G; Chiusolo, P; De Padua, L; Sica, S; Leone, 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 82 KB